The Filing Desk

SS Innovations International vs TriSalus Life Sciences

SS Innovations International SSII · TriSalus Life Sciences TLSI · Health Care Equipment

TriSalus Life Sciences reported revenue of $45 million in fiscal 2025, about the same as SS Innovations International's $42 million in fiscal 2025. SS Innovations International's revenue grew 105.7% in its latest year, and TriSalus Life Sciences' grew 53.4%. SS Innovations International had an operating margin of -19.3%, against -59.7% at TriSalus Life Sciences. Free cash flow was −$22 million at SS Innovations International and −$19 million at TriSalus Life Sciences.

Side by side

SS Innovations InternationalTriSalus Life Sciences
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Dec 31, 2025
Revenue$42M$45M
Revenue growth105.7%53.4%
Revenue growth a year, last 5 years——
Gross margin46.0%84.6%
Operating margin−19.3%−59.7%
Net margin−28.6%−86.9%
Free cash flow−$22M−$19M
Free cash flow margin−52.3%−41.9%
Return on capital——
Net debt to EBITDA——
Dividends and buybacks$0M$0M
Change in diluted share count9.7%49.6%
Last close$1.28$2.17
P/E at the last close——
Insider trades, last 12 monthsbought $5.2 million, sold $99,999bought $3.7 million, sold $137,130
Piotroski F-score—3 of 9
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
SS Innovations InternationalTriSalus Life Sciences
Operating margin
Percent of revenue
SS Innovations InternationalTriSalus Life Sciences
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
SS Innovations InternationalTriSalus Life Sciences

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the SS Innovations International and TriSalus Life Sciences pages.